Loading
A phase 1/2 trial of Paclitaxel / nab-paclitaxel in head and neck squamous cell carcinoma, run by Suzhou Junde Biotechnology Co., Ltd, active and no longer recruiting.
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma is a phase 1/2 interventional study registered as NCT04843098 by Suzhou Junde Biotechnology Co., Ltd, with 108 participants planned, started 2021-05-26 and due to reach its primary completion in 2024-11-20. Interventions recorded: TL117, Paclitaxel. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/